Skip To Main Content
US Healthcare Professionals Site

ACTEMRA® (tocilizumab)‎ ALECENSA® (alectinib) Avastin® (bevacizumab) COTELLIC® (cobimetinib) ENSPRYNG® (satralizumab-mwge) Erivedge® (vismodegib) Esbriet® (pirfenidone) Evrysdi® (risdiplam) GAVRETO® (pralsetinib) GAZYVA® (obinutuzumab) HEMLIBRA® (emicizumab-kxwh) Herceptin® (trastuzumab) Herceptin HYLECTA® (trastuzumab and hyaluronidase-oysk) KADCYLA® (ado-trastuzumab emtansine) LUCENTIS® (ranibizumab injection) OCREVUS® (ocrelizumab) PERJETA® (pertuzumab) PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) POLIVY® (polatuzumab vedotin-piiq) Pulmozyme® (dornase alfa) Inhalation Solution Rituxan® (rituximab) for Rheumatoid Arthritis (RA) RITUXAN® (rituximab) for Oncology Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV) RITUXAN HYCELA® (rituximab/hyaluronidase human) ROZLYTREK® (entrectinib) SUSVIMO™ (ranibizumab injection) TECENTRIQ® (atezolizumab) VABYSMO™ (faricimab-svoa) VENCLEXTA® (venetoclax tablets) XELODA® (capecitabine) XOLAIR® (omalizumab) for subcutaneous use ZELBORAF® (vemurafenib) Oncology Ophthalmology Rheumatology

ACTEMRA® (tocilizumab)‎ ALECENSA® (alectinib) Avastin® (bevacizumab) COTELLIC® (cobimetinib) ENSPRYNG® (satralizumab-mwge) Erivedge® (vismodegib) Esbriet® (pirfenidone) Evrysdi® (risdiplam) GAVRETO® (pralsetinib) GAZYVA® (obinutuzumab) HEMLIBRA® (emicizumab-kxwh) Herceptin® (trastuzumab) Herceptin HYLECTA® (trastuzumab and hyaluronidase-oysk) KADCYLA® (ado-trastuzumab emtansine) LUCENTIS® (ranibizumab injection) OCREVUS® (ocrelizumab) PERJETA® (pertuzumab) PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) POLIVY® (polatuzumab vedotin-piiq) Pulmozyme® (dornase alfa) Inhalation Solution Rituxan® (rituximab) for Rheumatoid Arthritis (RA) RITUXAN® (rituximab) for Oncology Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV) RITUXAN HYCELA® (rituximab/hyaluronidase human) ROZLYTREK® (entrectinib) SUSVIMO™ (ranibizumab injection) TECENTRIQ® (atezolizumab) VABYSMO™ (faricimab-svoa) VENCLEXTA® (venetoclax tablets) XELODA® (capecitabine) XOLAIR® (omalizumab) for subcutaneous use ZELBORAF® (vemurafenib) Oncology Ophthalmology Rheumatology

Here you can download the form you need to enroll in Genentech Access Solutions.

To get started, fill out the Patient Consent Form. There are 3 ways to send us the Patient Consent Form:

Cursor icon

Complete it online

Complete it online by selecting the eSubmit icon below

Phone icon

Text a photo

Text a picture of the completed form to (650) 877-1111

Fax icon

Send it via fax

Fill out a paper copy and fax it or mail it to us (or give it to your doctor to do so)

Doctor Icon

Your doctor also has to fill out the Prescriber Service Form. Once we have both these forms, we can begin working with you and your doctor’s office. You do not need to fill out anything on the Prescriber Service Form.

If you have been prescribed VENCLEXTA® (venetoclax tablets), you must fill out the VENCLEXTA Patient Consent Form. Please see VENCLEXTA Forms and Documents to find this form.

If you or your child has been prescribed Evrysdi® (risdiplam), you must fill out the patient consent section of the Evrysdi Start Form. Please see Evrysdi Forms and Documents to find this form.

eSubmit View Download
Download Selected 0 files selected Files will be downloaded as .zip file.

  • Complete and submit a form electronically.